✦ LIBER ✦

Orchidectomy versus buserelin in combination with CPA for 2 weeks or continuously in the treatment of metastatic prostate cancer (EORTC 30843)

✍ Scribed by de Voogt, HJ

Book ID: 123467360
Publisher: Elsevier Science
Year: 1990
Weight: 130 KB
Volume: 26
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(90)90317-M

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Orchidectomy versus buserelin in combina

Orchidectomy versus buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843

✍ de Voogt, H.J.; Klijn, J.G.M.; Studer, U.; Schröder, F.; Sylvester, R.; De Pauw, 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Orchidectomy versus goserelin plus fluta

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853)

✍ F. Keuppens; P. Whelan; J. L. De Carneiro Moura; D. Newling; A. Bono; L. Denis; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

Short-term versus long-term addition of

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer

✍ J. G. M. Klijn; H. J. De Voogt; U. E. Studer; F. H. Schröder; R. Sylvester; M. D 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB 👁 3 views

Aflibercept versus placebo in combinatio

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

✍ Tannock, Ian F; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla Thellenberg; Fl 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 310 KB

A phase 3 tRial comparing capecitabinE i

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

✍ José Baselga, Frederico Costa, Henry Gomez, Clifford A Hudis, Bernardo Rapoport… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 246 KB

476 PFS by patient subgroup for standard

476 PFS by patient subgroup for standard chemotherapies in combination with bevacizumab (BV) in the first-line treatment of HER2-negative locally recurrent (LR) or metastatic breast cancer (mBC): results from RIBBON-1

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB